Merck Serono Increases Oncology Medical Representatives To Expand Japanese Market
This article was originally published in PharmAsia News
Executive Summary
With the recent market launch of colon cancer drug Erbitux (cetuximab), German drug maker Merck Serono plans to add 20 to 40 oncology medical representatives in three years in Japan. Merck Serono currently has 60 oncology MRs in Japan. Merck Serono's president estimated that as colon cancer will likely top cancer cases in Japan by 2020, Erbitux could become a blockbuster drug. (Click here for more - Japanese language